Archive for December 2005
Treatment Efficacy of Combination-Therapy
Post T.M., Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period. PAGE.(2005). [Link to publication]
Read MoreRobust fitting of pharmacokinetic models to Phase II/III clinical trial data
Freijer J., Greef I.d., Post T. and Ploeger B., Robust fitting of pharmacokinetic models to Phase II/III clinical trial data. PAGE.(2005). [Link to publication]
Read MoreMechanistic Disease Progression Analysis Indicates that Pioglitazone Improves ß-cell Function in Treatment-naïve Type 2 Diabetics
Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Improves ß-cell Function in Treatment-naïve Type 2 Diabetics. ADA.(2005).
Read MoreTreatment efficacy of Pioglitazone in Combination Therapy
Post T., Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Treatment efficacy of Pioglitazone in Combination Therapy on Disease Progression in Type 2 Diabetes Mellitus over a two-year period. ADA.(2005).
Read MoreCascading Disease Progression Analysis in Type 2 Diabetes
Winter W.d., Cascading Disease Progression Analysis in Type 2 Diabetes: Integrating multiple biomarkers into single mechanism-based model. PharmSciFair.(2005).
Read MoreTreatment Efficacy of Combination-Therapy
Post T.M., Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period. Figon.(2005).
Read MorePharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor
Schaddelee M.P., Collins S.D., Jongh J.d., Boer A.G.d., Ijzerman A.P. and Danhof M., Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain, Eur J Pharmacol, 514(2-3): 131-140, 2005. [Link to publication]
Read MorePopulation pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients
Swart E.L., Jongh J.d., Zuideveld K.P., Danhof M., Thijs L.G. and Strack van Schijndel R.J., Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration, Am J Kidney Dis., 45(2): 360-371., 2005. [Link to publication]
Read MoreBasic disease progression models in degenerative disease
Post T.M., Freijer J.I., Jongh J.d. and Danhof M., Disease system analysis: basic disease progression models in degenerative disease, Pharm Res, 22(7): 1038-1049., 2005. [Link to publication]
Read MorePopulation pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo
Liefaard L.C., Ploeger B.A., Molthoff C.F., Boellaard R., Lammertsma A.A., Danhof M. and Voskuyl R.A., Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography, Mol Imaging Biol., 7(6): 411-421., 2005. [Link to publication]
Read More